The choice of the treatment strategies largely depends on the molecular subtyping based on the expression status of estrogen receptors (e.g., ERα and ERβ) and human epidermal growth factor receptor 2 (HER2) as well as breast cancer stage [5]. This evidence concerns the gene ESR1 and breast carcinoma.